VECTA Ltd. is using safe and novel physiological approaches to create products for the multibillion-dollar Gastrointestinal (GI) diseases market. A particular emphasis is being put on diseases that are usually treated by proton pump inhibitors (PPIs), a group of drugs, the patents of which have now begun to expire. We specialize in making good medications even better by overcoming the limitations of current medications unmet medical needs through inventive combination therapies.
We are developing products for the treatment of acid-dependent and H. pylori-associated disorders.
We have succeeded in bringing our lead product, VECAM, from a mere concept to Phase IIb clinical trials.
Our multidisciplinary team is developing our compounds through an integrated approach, keeping in mind the potential of strategic partnerships.